Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785

Homologous and Heterologous Covid-19 Booster Vaccinations

Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., Sahly, H. M. E., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116414 · Cited by 646

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627

Humoral and cellular immune memory to four COVID-19 vaccines

Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 576

Innate immune mechanisms of mRNA vaccines

Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 535

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 462

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.018 · Cited by 475

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Covid-19 Vaccines — Immunity, Variants, Boosters

Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 451

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S. M. J., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 406

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119658 · Cited by 387

Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)

Miller, J. M., Binnicker, M. J., Campbell, S. M., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 419

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

(2021) · doi:10.1126/science.abj9853 · Cited by 327

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Lipsitch, M., Krammer, F., Regev‐Yochay, G., Lustig, Y., & Balicer, R. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 345

Correlates of protection against SARS ‐ CoV ‐2 infection and COVID‐19 disease

Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 301

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04778-y · Cited by 297

A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma

Najjar, D., Rainbow, J., Sanjay, S. T., Jolly, P., de Puig, H., Yafia, M., Durr, N., Sallum, H. M., Alter, G., Li, J. Z., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00919-w · Cited by 304

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · Science · doi:10.1126/science.abq0839 · Cited by 264

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 260

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 237

A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines

Gilbert, P. B., Donis, R. O., Koup, R. A., Fong, Y., Plotkin, S. A., & Follmann, D. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2211314 · Cited by 217

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 225

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection

Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 225

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225

Structural Diversity of the SARS-CoV-2 Omicron Spike

Gobeil, S., Henderson, R. C., Stalls, V., Janowska, K., Huang, X., May, A. J., Speakman, M., Beaudoin, E. L., Manne, K., Li, D., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.028 · Cited by 206

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 211

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

Quandt, J., Muik, A., Salisch, N. C., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A.-K., Adams‐Quack, P., Bacher, M., Finlayson, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2427 · Cited by 194

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 209

COVID-19 vaccination: The road ahead

Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 198

Imprinted SARS-CoV-2-Specific Memory Lymphocytes Define Hybrid Immunity

Rodda, L. B., Morawski, P. A., Pruner, K. B., Fahning, M. L., Howard, C. A., Franko, N., Logue, J. K., Eggenberger, J., Stokes, C., Golez, I., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.018 · Cited by 200

A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike

Dadonaite, B., Crawford, K. H. D., Radford, C. E., Farrell, A. G., Yu, T. C., Hannon, W. W., Zhou, P.-P., Andrabi, R., Burton, D. R., Liu, L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.001 · Cited by 186

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Sanders, J., Bemelman, F. J., Messchendorp, A. L., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Frölke, S. C., Geers, D., GeurtsvanKessel, C. H., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003983 · Cited by 182

T Cell Responses to SARS-CoV-2

Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 191

The Evolution and Biology of SARS-CoV-2 VariantsPreprint

Telenti, A., Hodcroft, E. B., & Robertson, D. L. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041390 · Cited by 191

Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events

Ng, S. C., Peng, Y., Zhang, L., Mok, C. K. P., Zhao, S., Li, A., Ching, J. Y. L., Liu, Y., Yan, S., Chan, D. L. S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326563 · Cited by 186

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

Creech, C. B., Anderson, E. J., Berthaud, V., Yildirim, I. B., Atz, A. M., Baez, I. M., Finkelstein, D., Pickrell, P., Kirstein, J., Yut, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203315 · Cited by 174

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153

Towards a population-based threshold of protection for COVID-19 vaccines

Goldblatt, D., Fiore-Gartland, A. J., Johnson, M., Hunt, A., Bengt, C., Zavadska, D., Snipe, H. D., Brown, J., Workman, L., Zar, H. J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.006 · Cited by 172

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

Bowen, J. E., Addetia, A., Dang, H. V., Stewart, C., Brown, J. T., Sharkey, W. K., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., et al. (2022) · Science · doi:10.1126/science.abq0203 · Cited by 160

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants

Servellita, V., Syed, A. M., Morris, M. K., Brazer, N., Saldhi, P., Garcia-Knight, M., Sreekumar, B. K. N., Khalid, M. M., Ciling, A., Chen, P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.019 · Cited by 155

Shedding of infectious SARS-CoV-2 despite vaccination

Riemersma, K. K., Haddock, L. A., Wilson, N. A., Minor, N. R., Eickhoff, J. C., Grogan, B., Kita-Yarbro, A., Halfmann, P., Segaloff, H. E., Kocharian, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010876 · Cited by 169

Antiviral neutralizing antibodies: from in vitro to in vivo activity

Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 168

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

Khoury, D. S., Schlub, T. E., Cromer, D., Steain, M. C., Fong, Y., Gilbert, P. B., Subbarao, K., Triccas, J. A., Kent, S. J., & Davenport, M. P. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221422 · Cited by 158

Characterization of nanoparticles-based vaccines for COVID-19

Guerrini, G., Magrì, D., Gioria, S., Medaglini, D., & Calzolai, L. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01129-w · Cited by 157

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Zhou, P.-P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 154

mRNA vaccine in cancer therapy: Current advance and future outlook

Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 134

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 145

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19

Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139

Neutralising antibodies predict protection from severe COVID-19

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Follmann, D. A., Janes, H., Buhule, O. D., Zhou, H., Girard, B., Marks, K., Kotloff, K. L., Desjardins, M., Corey, L., Neuzil, K. M., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1300 · Cited by 127

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines

Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 141

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients

Ruether, D. F., Schaub, G., Duengelhoef, P. M., Haag, F., Brehm, T. T., Fathi, A., Wehmeyer, M. H., Jahnke-Triankowski, J., Mayer, L., Hoffmann, A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.003 · Cited by 133

CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques

Liu, J., Yu, J., McMahan, K., Jacob-Dolan, C., He, X., Giffin, V., Wu, C., Sciacca, M., Powers, O., Nampanya, F., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq7647 · Cited by 132

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Barnes, E. J., Goodyear, C. S., Willicombe, M. K., Gaskell, C., Siebert, S., de Silva, T. I., Murray, S. M., Rea, D. W., Snowden, J. A., Carroll, M. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02414-4 · Cited by 132

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02031-7 · Cited by 131

Count on us: T cells in SARS-CoV-2 infection and vaccination

Kedzierska, K., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100562 · Cited by 124

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Gilbert, P. B., Huang, Y., deCamp, A. C., Karuna, S., Zhang, Y., Magaret, C. A., Giorgi, E. E., Korber, B., Edlefsen, P. T., Rossenkhan, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01953-6 · Cited by 122

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S. J., Davenport, M. P., & Cromer, D. (2023) · Nature Medicine · doi:10.1038/s41591-023-02228-4 · Cited by 104

Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 106

Accelerated waning of the humoral response to COVID-19 vaccines in obesity

van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02343-2 · Cited by 106

Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike

Stalls, V., Lindenberger, J. J., Gobeil, S., Henderson, R. C., Parks, R., Barr, M., Deyton, M., Martin, M., Janowska, K., Huang, X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111009 · Cited by 101

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01212-3 · Cited by 95

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/d41586-021-03846-z · Cited by 114

Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile

(2022) · doi:10.1038/s41564-022-01092-1 · Cited by 98

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review

Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Greenberger, L. M., Saltzman, L. A., Senefeld, J. W., Johnson, P. W., DeGennaro, L. J., & NICHOLS, G. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.001 · Cited by 94

Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies

Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 120

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines

Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 104

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

Perry, J. A., Osman, S., Wright, J., Richard‐Greenblatt, M., Buchan, S. A., Sadarangani, M., & Bolotin, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266852 · Cited by 93

B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity

Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01262-1 · Cited by 92

Aging, inflammaging and immunosenescence as risk factors of severe COVID-19

Tizazu, A. M., Mengist, H. M., & Demeke, G. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00309-5 · Cited by 96

Recent updates on correlates of vaccine-induced protection

Plotkin, S. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081107 · Cited by 89

Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019: Serologic Testing

Hayden, M. K., Mikati, I. K. E., Hanson, K. E., Englund, J. A., Humphries, R. M., Lee, F., Loeb, M. B., Morgan, D. J., Patel, R., Ta’ani, O. A., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae121 · Cited by 89

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89

Vaccine protection against the SARS-CoV-2 Omicron variant in macaques

Chandrashekar, A., Yu, J., McMahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D. L., Anioke, T., Barrett, J., Chung, B., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.024 · Cited by 82

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 84

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek, A., Boyton, R. J., Peckham, N., McKnight, Á., Coates, L. C., Bluett, J., Barber, V. S., Cureton, L., Francis, A., Appelbe, D. E., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00186-2 · Cited by 84

Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis

Grifoni, A., Alonzi, T., Alter, G., Noonan, D. M., LANDAY, A. L., Albini, A., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146704 · Cited by 90

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Sullivan, D. J., Franchini, M., Joyner, M. J., Casadevall, A., & Focosi, D. (2022) · Nature Communications · doi:10.1038/s41467-022-33864-y · Cited by 92

Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study

Barin, B., Kasap, U., Selçuk, F., Volkan, E., & Uluçkan, Ö. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00305-0 · Cited by 80

Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates

Suzuki, Y., Miyazaki, T., Muto, H., Kubara, K., Mukai, Y., Watari, R., Sato, S., Kondo, K., Tsukumo, S., Yasutomo, K., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.017 · Cited by 83

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., et al. (2022) · Med · doi:10.1016/j.medj.2022.02.006 · Cited by 68

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Dashdorj, N., Wirz, O. F., Röltgen, K., Haraguchi, E., Buzzanco, A. S., Sibai, M., Wang, H., Miller, J. A., Solis, D., Sahoo, M. K., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.004 · Cited by 76

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

Huang, Y., Borisov, O., Kee, J. J., Carpp, L. N., Wrin, T., Cai, S., Sarzotti‐Kelsoe, M., McDanal, C. B., Eaton, A., Pajón, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03154-6 · Cited by 74

SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines

Bowen, J. E., Park, Y., Stewart, C., Brown, J. T., Sharkey, W. K., Walls, A. C., Joshi, A., Sprouse, K. R., McCallum, M., Tortorici, M. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.adf1421 · Cited by 81

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00287-7 · Cited by 76

The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future

Antinori, A., & Bausch-Jurken, M. T. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad181 · Cited by 76

Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections

Stærke, N. B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L. S., Iversen, M. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32254-8 · Cited by 74

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162